The user facility reported to terumo cardiovascular that prior to cardiopulmonary bypass during prime, there was a leak at the purge line.Per facility, they clamped it off and moved the sampling line.*no known impact or consequence to patient.*the product was not changed out.*the surgery was completed successfully.
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on october 6, 2022.Upon further investigation of the reported event, the following information is new and/or changed: h6 (identification of evaluation codes 11, 3331, 4114, 3259, 4307).Type of investigation #1: 11 - testing of device from same lot/batch retained by manufacturer.Type of investigation #2: 3331 - analysis of production records.Type of investigation #3: 4114 - device not returned.Investigation finding: 3259 - improper physical structure.Investigation conclusions: 4307 - cause traced to component failure.The affected sample was not returned.However, a photo was provided showing a leak at the arterial pigtail port which confirms this event.A representative retention sample was inspected to confirm no visual damage or anomalies with the arterial pigtail.All capiox units are 100% visually inspected at several points in the production process.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|